Novavax Stock Reverses Gains as Market Realizes Company Has No Plague Vaccine
Novavax shares surged 20% on Monday after a possible pneumonic plague death in Russia sparked speculation about emergency vaccine orders, then fell 12% the next day when the WHO downgraded risk assessments. The sell-off highlighted a critical fact: Novavax manufactures COVID vaccines, not plague vaccines, making the initial rally entirely disconnected from the company's actual product portfolio. Analysts project revenue declining from $1.12 billion in 2025 to $373 million in 2026, with the stock currently trading at over 8 times forward sales compared to its five-year average of 2.3 times.
The market's Monday rally was triggered by a death at a Russian laboratory that sparked initial concern about a potential plague outbreak. Investors speculated that governments might place emergency vaccine orders, causing both Novavax and Moderna to surge. The WHO's swift risk assessment the following day—concluding that plague transmission was unlikely and contacts tested negative—deflated those expectations almost immediately, erasing the majority of gains in a single trading session.
Beyond the immediate volatility, Novavax faces structural headwinds. The company's revenue stream is contracting sharply as COVID vaccine demand normalizes and royalty payments decline. With projected revenue falling more than two-thirds between 2025 and 2027, the company's financial runway depends heavily on milestone payments from manufacturing partnerships, including a $75 million checkpoint from Sanofi expected in mid-2027.
This episode illustrates how market sentiment can disconnect from fundamentals during uncertainty. Investors holding Novavax stock experienced significant volatility based on speculative scenarios that bore no relation to the company's actual business. Stakeholders including shareholders, employees, and partners may face consequences if valuation corrections accelerate, while the incident also highlights how biotech companies can see equity prices swing sharply on rumors of disease outbreaks—potentially affecting capital availability for genuine vaccine development efforts.